Description

This webinar will be viewed at the GCA Conference. No link will be provided.

Thursday, August 27, 2026 |  2:00 pm - 3:30 pm (EDT) | 8 AM - 9:30 AM HST

Description:

The proposed federal rescheduling of marijuana has raised important questions about workplace drug testing, safety programs, and employer compliance. While the process is still underway, organizations should understand what a move from Schedule I to Schedule III would—and would not—change. This webinar will separate fact from speculation, examine the potential impact on workplace drug testing and employer policies, explore the intersection of federal and state laws, and provide practical steps employers can take to maintain safe workplaces while preparing for future legal developments.

By attending this webinar, participants will:

• Describe the Controlled Substances Act scheduling system and summarize the potential implications of the proposed federal rescheduling of marijuana for employers.
• Distinguish between the legal and regulatory changes associated with federal marijuana rescheduling and the workplace drug testing and safety requirements that remain unchanged.
•  Analyze how federal regulations, state marijuana laws, and safety-sensitive job classifications may affect workplace drug testing policies and compliance obligations.
• Assess workplace policies and procedures related to drug testing, supervisor training, reasonable suspicion determinations, and accommodation requests in response to evolving cannabis laws.
• Evaluate strategies for addressing marijuana impairment and fitness-for-duty concerns to support workplace safety, particularly in safety-sensitive environments.

Featured Speakers

Nick Hartman
Drug Screening Compliance Institute (DSCI)
Co-Founder & Managing Partner

William J. Judge JD, LL.M.
Drug Screening Compliance Institute (DSCI)
Co-Founder, Senior Research Attorney